Tectonic Advisors 13F: Exits Incyte (INCY) Stake

Tectonic Advisors sold out of its stake in Incyte Corporation INCY, parting ways with all 8,613 shares during the quarter. The exit was revealed in a Form 13F filing with the SEC on October 22, 2026. The firm held 8,613 shares prior to the complete sell-off.

INCY Incyte Corporation

$116.93 ▲ +15.29% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Tectonic Advisors's Incyte Corporation Position

During the quarter, Tectonic Advisors wrapped up its investment in the biotechnology firm by liquidating the entirety of its 8,613 shares. The complete exit reduced the holding down to zero shares.

Other Institutional Activity in Incyte Corporation

Baker Bros. Advisors, LP grew its holdings by 18,446 shares, ending with 30,762,330 shares worth about $3.55 billion. Dodge & Cox Inc. reduced its holdings by 295,288 shares, ending with 11,957,326 shares worth about $1.38 billion. AQR Capital Management, LLC reduced its holdings by 487,309 shares, ending with 5,320,901 shares worth about $614.17 million. LSV Asset Management grew its holdings by 203,836 shares, ending with 4,123,759 shares worth about $475.98 million.

Incyte Corporation Stock Up 2.5%

Incyte Corporation shares recently traded around $116.31 as of October 23, 2026, sitting below the closing price of $116.93 recorded on October 22, 2026. The stock sits below its 50-day moving average and above its 200-day moving average. It trades below its 52-week high of $132.60 and above its 52-week low of $84.02.

Recent Earnings

Incyte Corporation recently reported trailing twelve month revenue of $5.82 billion alongside a trailing P/E ratio of 14.90. Profitability metrics include a net profit margin of 27.7% and a return on equity of 30.7%. Earnings stand at $7.85 per share on a trailing basis. Its next earnings report is scheduled for October 29, 2026.

Insider Buying and Selling at Incyte Corporation

Company insiders were active during the period, including Pablo J. Cagnoni, who made multiple transactions prior to the filing date, such as selling 26,422 shares on October 15, 2026.

Analysts Set New Price Targets

Analysts updated their views on the stock ahead of the filing. Stifel maintained a buy rating on October 5, 2026, while raising its price target to $157.00. Overall, the stock carries a consensus buy recommendation from 24 analysts with a mean price target of $129.54.

About Incyte Corporation

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company that discovers, develops, and brings to market targeted therapeutics for patients. The firm focuses on finding new treatment options in life-science fields where medical needs remain high. Institutional shifts in ownership arrive as the company advances its clinical pipelines and commercial products.

Bottom Line

Investors continue to monitor institutional shifts and upcoming financial updates for Incyte Corporation. The company's next earnings report on October 29, 2026, will offer fresh insight into its financial performance.